Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the company has been assigned two provisional patent applications from Memorial Sloan-Kettering Cancer Center (MSK). The company's license, Development and Commercialization Agreement (License Agreement) with MSK, which already included issued patents that pertain to Actinium's Alpha Particle Immunotherapy (APIT) technology platform and drug preparation methods now includes these newly assigned provisional patent applications.

 About Alpha Particle Immunotherapy (APIT) platform

Actinium's Alpha Particle Immunotherapy (APIT) platform is a highly potent and selective form of targeted payload radioimmunotherapy. The APIT platform is based on attaching the powerful alpha emitting radioisotope Actinium-225 to monoclonal antibodies (mAbs), which are large molecules capable of binding specifically to cancer cells. By virtue of carrying alpha emitters, mAbs bring Actinium-225 directly to cancer cells where alpha emitters can selectively kill the targeted cell. Actinium-225 emits significant energy making it a potent against targeted cancer cells but this energy only travels extremely short distances limiting damage to healthy tissues. Due to the targeting of this energy by way of the mAbs bringing the alpha emitting isotopes directly to cancer cells, Actinium believes Actinium-225 enabled therapies will result in potentially more effective and at the same time tolerable therapies.

To read more please visit: http://ir.actiniumpharma.com/press-releases/detail/178

Source: Actinium Pharmaceuticals